The Department of Neurosurgery at the University of Texas Health Science Center at San Antonio (UTHSCSA) is dedicated to providing compassionate, skilled and state of the art medical care. As a nationally recognized medical center, we continue to experience unprecedented growth and expansion in both the clinical and academic arenas. Our primary mission is to provide helpful and considerate patient care. We also aim to educate and produce highly qualified, ethical and caring future neurosurgeons. Additionally, we strive to advance the field of neurosciences by performing outstanding research.
| Tuesday Apr 18, 2017 |
Medicenna Treats First Patient in Phase 2b Recurrent Glioblastoma Trial
| Thursday Apr 13, 2017 |
HOUSTON and TORONTO, April 13, 2017 /PRNewswire/ - Medicenna BioPharma Inc. ("Medicenna" or "the Company"), a wholly owned subsidiary of Medicenna Therapeutics Corp., a publicly listed clinical stage immuno-oncology company (TSXV: "MDNA"), today announced that it has treated the first patient in its Phase 2b clinical trial of MDNA55, the Company's lead candidate. MDNA55 is being developed for the treatment of recurrent glioblastoma (rGB), the most common and uniformly fatal form of brain cancer.
"Dosing the first patient in this clinical trial is a significant milestone for the Company as we look to build upon the promising results from earlier studies with MDNA55," said Dr. Fahar Merchant, Chairman and CEO of Medicenna. "We are pleased to be working with leading neuro-surgical centers in the U.S. as we explore the benefits of MDNA55 for the treatment of rGB and other types of brain cancer."
MDNA55 is a targeted form of immunotherapy designed to purge tumor cells and adjacent immunosuppressive cells in the tumor microenvironment that over-express the interleukin-4 receptor (IL4R), which is common in a majority of patients with rGB. By directly eliminating tumor cells and boosting a therapeutic immune response in rGB patients, MDNA55 provides a two-pronged approach to treat brain cancer patients.
The primary endpoint is overall response rate (ORR), assessed by magnetic resonance imaging using the Revised Assessment in Neuro-Oncology (RANO) criteria. Secondary outcome measures include progression-free survival, overall survival, and exploratory predictors of outcome assessed by IL4R expression in archived tumor biopsies.
The study will be conducted in approximately ten sites in the United States. Patient enrolment is expected to be completed before the end of 2017 with top-line results anticipated in the first half of 2018.
A summary of clinical data from earlier Phase 1 and 2 clinical trials can be found on Medicenna Therapeutics Corp.'s website at http://www.medicenna.com/Our-Lead-Program/Clinical-Development/default.aspx.
This news release contains forward-looking statements relating to the future operations of the Company and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release, including, without limitation, statements regarding the expansion of the clinical program to other types of brain cancer, that MDNA55 provides a two-pronged approach to treat brain cancer patients, that MDNA55 has the potential to alter the treatment paradigm for brain cancer, that we expect enrolment to be completed by the end of calendar 2017 with top-line results anticipated in the first half of 2018, future plans and objectives of the Company and others are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations include the risks detailed in the filing statement of the Company dated February 27, 2017 and in other filings made by the Company with the applicable securities regulators from time to time.
The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements only as expressly required by Canadian securities law.
| Thursday Apr 6, 2017 |
Each year hundreds of medical students, residents, and fellows showcase their research at Passport, the largest research meeting held at UT Health San Antonio. This annual event, co-sponsored by the School of Medicine’s Research and Graduate Medical Education offices, provides participants with the opportunity to present posters covering topics related to research, quality improvement, and patient safety. This year, the Department of Neurosurgery was represented by more than 20 medical students working under the mentorship of Dr. Ali Seifi. We are proud of their accomplishments and excited to share some photos of the event with you.